Hint mode is switched on Switch off
For swift navigation between sections

Esperion Therapeutics
LEI 549300OFU56UKEWVUS92

PDF download

Choose all Reset all
Download Cancel
Organization name
Esperion Therapeutics, Inc.
Country name
USA
Country of registration
USA
Industry
Pharmaceutical Preparation and Biotechnology
Public debt
100 mln USD
Welcome to Cbonds
New to Cbonds? · Take a 90-second tour of the platform.

Discover what you can do with Cbonds

Everything you need for fixed income research and monitoring.

  • 00:23 Coverage
  • 00:40 Bond screener
  • 00:54 Parameters
  • 01:10 Watchlist, Mobile app
  • 01:15 Excel Add-in
Get access Watch full tour

Latest data on

Get access to the largest financial database

Try in 7-days Demo access

Free for company representative

  • Evaluate advanced analytical tools
  • Get full online access to the database
  • Try our powerful bond screener
  • Track bond prices from 400+ sources

Get access to the largest financial database

Representative of the company 7 days FREE trial

Professional access to the data

Private investor

Individual access

Quotes

Request sent
Access denied
Send request
Quotes provided by information providers are indicative in nature

Profile

Esperion Therapeutics, Inc., a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C).

Awards

News

13/07/2026 Esperion Therapeutics: Entry Into A Material Definitive Agreement, Termination Of A Material Definitive Agreement, Completion Of Acquisition Or Disposition Of Assets, Creation Of A Direct Financial Obligation Or An Obligation Under An Offbalance Sheet Arrangement Of A Registrant, Notice Of Delisting Or Failure To Satisfy A Continuing Listing Rule Or Standard; Transfer Of Listing, Material Modification To Rights Of Security Holders, Changes In Control Of Registrant, Departure Of Directors; Election Of Directors, Amendments To Articles Of Incorporation Or Bylaws; Changes In Fiscal Year, Financial Statements And Exhibits
08/07/2026 Esperion Therapeutics: Submission Of Matters To A Vote Of Security Holders
02/06/2026 Esperion Therapeutics: Other Events
02/04/2026 Esperion Therapeutics: Of The Original Report To Present The Required Financial Statements And Pro Forma Financial Information Not Later Than 71 Calendar Days From The Date On Which The Original Report Was Required To Be Filed, As Permitted Under Items 9.01(a)(3) And 9.01(b)(2). Except For The Filing Of Such Financial Statements And Pro Forma Financial Information, This Amendment Does Not Otherwise Modify Or Update The Original Report, And This Amendment Should Be Read In Conjunction With The Original Report
02/03/2026 Esperion Therapeutics: Entry Into A Material Definitive Agreement, Regulation Fd Disclosure, Financial Statements And Exhibits
All organization news

Documentation

IFRS/US GAAP reports

2026
I q eng
2025
I q eng
II q eng
III q eng
2024
I q eng
II q eng
III q eng
IV q eng
2023
I q eng
II q eng
III q eng
IV q eng
2022
I q eng
II q eng
III q eng
IV q eng
2021
I q eng
II q eng
III q eng
IV q eng
2020
I q eng
II q eng
III q eng
IV q eng
2019
I q eng
II q eng
III q eng
IV q eng
2018
I q eng
II q eng
III q eng
IV q eng
2017
I q eng
II q eng
III q eng
IV q eng
2016
I q eng
II q eng
III q eng
IV q eng
2015
I q eng
II q eng
III q eng
IV q eng
2014
IV q eng
Show all Hide
Authorization required
You need to request access

Stocks

Latest issues

Show all

Public debt by currencies

Show more Hide

Codes

  • LEI
    549300OFU56UKEWVUS92
  • SIC
    2834 PHARMACEUTICAL PREPARATIONS
  • NACE
    *** ***
  • NAICS
    *** ***
  • CIK
    0001434868
Registration is required to get access.